Sparsentan is under clinical development by Travere Therapeutics and currently in the Phase II, Phase III and Pre-Registration in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Sparsentan’s likelihood of approval (LoA) and phase transition for IgA Nephropathy (Berger’s Disease) took place on 17 May 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Sparsentan Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Sparsentan overview

Sparsentan (RE-021, PS-433540) is under development for the treatment of immunoglobulin A vasculitis (IgAV), ANCA-associated Vasculitis, alport syndrome (AS), focal segmental glomerulosclerosis and IgA nephropathy (Berger's disease). It is administered by the oral route.RE-021 is a dual-acting receptor antagonist (DARA) that targets the angiotensin II receptor type 1 (AGTR1) and endothelin A receptor (ETA). It was also under development for the treatment of hypertension, metabolic disease.

Travere Therapeutics overview

Travere Therapeutics, formerly Retrophin, is a biopharmaceutical company that discovers, develops, acquires, and markets drugs for the treatment of rare diseases. The company’s products include thiola, chenodal and cholbam. It develops drugs for therapies to people living with rare kidney, liver, and metabolic diseases. Travere Therapeutics pipeline products include sparsentan, used for the treatment of focal segmental glomerulosclerosis; RE-024, a product candidate to treat pantothenate kinase-associated neurodegeneration and RE-034, utilized for the treatment of severe rare diseases. The company markets its products through its distribution partners. It works in partnership with academia and independent researchers to support the development of novel solutions. Travere Therapeutics is headquartered in San Diego, California, the US.

Quick View Sparsentan LOA Data

Report Segments
  • Innovator
Drug Name
  • Sparsentan
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Genetic Disorders
  • Genito Urinary System And Sex Hormones
  • Immunology
  • Metabolic Disorders
Key Developers
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.